We are still in a bull market, but the biotech industry, as measured by the SPDR S&P Biotech ETF (an industry benchmark), hasn't been keeping up with broader equities this year. That's no reason to avoid biotech stocks -- after all, some are doing just fine.

That's the case with Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT). Although these drugmakers continue to perform well, both look to have plenty of upside. Let's find out why it's worth buying shares of each.

Continue reading

Source Fool.com